Supportive Care

Matthew Banegas, PhD, MPH, discusses a recent study that found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

The FDA approved single-dose fosaprepitant dimeglumine (Emend for injection) in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC), according to Merck, the developer of the drug.

Phillip J. Koo, MD, discusses the benefits of radium-223 and why he thinks it is time the use of the drug becomes more widespread for the treatment of mCRPC, and potentially other cancers.

As more studies link aggressive end-of-life oncology care to problems such as suboptimal cost and quality outcomes, experts are increasingly proposing earlier, more comprehensive palliative care interventions.

Prophylactic administration of standard heart failure medications helped preserve left ventricular ejection fraction in patients treated with trastuzumab for HER2-positive metastatic breast cancer.

Jimmie C. Holland, MD, whose emphasis on patients’ psychosocial needs helped humanize cancer care, was honored in the Supportive Care category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Brian Baumann, MD, medical oncologist, University of Pennsylvania, discusses the impact of skin creams on radiation.

Lawrence Fong, MD, Professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the importance of educating oncologists on the side effects of immunotherapies.

A novel service model that incorporated palliative care measures and shorter radiation treatment was associated with fewer unfinished treatments with radiation, shorter hospital stays, and increased use of palliative care for patients with bone metastases.

ASCO and AAHPM recently partnered to create a consensus definition of high-quality palliative care.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies.

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.

Jeanine Stiles, chief administrative officer, associate director for administration, UC Davis Comprehensive Cancer Center, discusses the importance of supportive care for patients with cancer.

Due to the unique characteristics of adolescents and young adults, there is a growing effort to address their oncology needs.

Marleen Meyers, MD, discusses rolapitant (Varubi), which the FDA recently approved to prevent delayed CINV.

The first FDA-approved biosimilar, Zarxio, is now available for patients in the United States, following a series of lawsuits and court decisions.

Alberto Montero, MD Staff Physician in the Department of Solid Tumor Oncology, Cleveland Clinic, discusses reducing readmission rates for oncology patients.

The FDA has approved aprepitant capsules in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting in patients aged 12 to 17 and for those under the age of 12 who weigh at least 30 kg who are receiving chemotherapy.

The FDA has approved rolapitant (Varubi) for use in combination with other antiemetic agents to prevent delayed CINV.